USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
VENATORX PHARMACEUTICALS, INC.
Address:
30 Spring Mill Drive
Malvern, PA 19355
Phone:
N/A
URL:
N/A
EIN:
127278219
DUNS:
962754037
Number of Employees:
18
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,800,000.00 3
SBIR Phase II $6,000,000.00 2

Award List:

Novel Metallo-beta-lactamase Inhibitors

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Luigi Xerri – 484-595-6990
Abstract:
DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as NDM-1 are found on mobile genetic elements which are rapidly spreading in Enterobacteriaceae and… More

Preserving beta-lactam utility against pathogens producing all classes of beta-la

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Christopher J. Burns – 610-213-0248
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only subclass of b-lactams (the monobactams) that are not sensitive to zinc-based enzymes (Ambler Class… More

Novel Compounds Targeting Bacterial PBPs

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Christopher J. Burns – 610-213-0248
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiotics (i.e., the Penicillin Binding Proteins, or PBPs), but with the prospect of avoiding n important… More

Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Luigi Xerri – 484-595-6990
Abstract:
DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. While carbapenems are among the most prescribed antibiotics for infections caused by these organisms, carbapenem resistance conferred by zinc-based metallo-carbapenemases (Amber Class… More

Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Christopher J. Burns – 610-213-0248
Abstract:
DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. This crisis has been further amplified by the recent emergence of the NDM-1 super-bug gene , a zinc-based metallo- -lactamase (Amber Class B), in Enterobacteriaceae. Members of… More